Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13185215 | 0.93 | ALDH1A1 (0.70) | ALDH1A1KDM4ESMN1; SMN2HTTTSHR | |
| SCHEMBL305458 | 0.87 | KDM4E (1.00) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL3646083 | 0.86 | KDM4E (0.62) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL109617 | 0.86 | LTA4H (0.59) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL3645465 | 0.86 | KDM4E (0.62) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL13766268 | 0.86 | KDM4E (0.97) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL14970709 | 0.86 | KDM4E (0.97) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL248444 | 0.85 | LTA4H (0.59) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL14578276 | 0.85 | ALDH1A1 (0.69) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H | |
| SCHEMBL26986155 | 0.85 | KDM4E (0.75) | ALDH1A1KDM4ESMN1; SMN2HTTLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-9365519-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9212181-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885KDM4E 3792/4885SMN1; SMN2 2352/4885 |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885KDM4E 3792/4885SMN1; SMN2 2352/4885 |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 2460/4885KDM4E 36/4885SMN1; SMN2 952/4885 |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | ARSA, BMP2, BMP1 | ALDH1A1 721/4885KDM4E 1873/4885SMN1; SMN2 1743/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885KDM4E 3792/4885SMN1; SMN2 2352/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | ALDH1A1 1821/4885KDM4E 4091/4885SMN1; SMN2 4552/4885 |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | ALDH1A1 4790/4885KDM4E 1613/4885SMN1; SMN2 3838/4885 |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | CYP24A1, SOST, ACP3 | ALDH1A1 537/4885KDM4E 2169/4885SMN1; SMN2 2523/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | ALDH1A1 4790/4885KDM4E 1613/4885SMN1; SMN2 3838/4885 |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885KDM4E 3792/4885SMN1; SMN2 2352/4885 |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | ALDH1A1 3729/4885KDM4E 3066/4885SMN1; SMN2 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.